

## Deciphering the functional role of RIPK4 in melanoma

Ewelina Madej<sup>1</sup>, Damian Ryszawy†<sup>2</sup>, Anna A. Brozyna<sup>3</sup>, Jaroslaw Czyz<sup>2</sup> Malgorzata Czyz<sup>4</sup> and Agnieszka Wolnicka-Glubisz<sup>1,\*</sup>

<sup>1</sup> Department of Biophysics, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland; e-mail: [ewel.madej@doctoral.uj.edu.pl](mailto:ewel.madej@doctoral.uj.edu.pl); [a.wolnicka-glubisz@uj.edu.pl](mailto:a.wolnicka-glubisz@uj.edu.pl)


<sup>2</sup> Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland; e-mail: [jarek.czyz@uj.edu.pl](mailto:jarek.czyz@uj.edu.pl)

<sup>3</sup> Department of Human Biology, Faculty of Biology and Veterinary Sciences, Nicolaus Copernicus University, Toruń, Poland; e-mail: [anna.brozyna@umk.pl](mailto:anna.brozyna@umk.pl)


<sup>4</sup> Department of Molecular Biology of Cancer, Medical University of Lodz, Lodz, Poland; e-mail: [malgorzata.czyz@umed.lodz.pl](mailto:malgorzata.czyz@umed.lodz.pl)

† Damian Ryszawy, PhD passed away on 11.09.2020




\*Correspondence: ul. Gronostajowa 7, 30-387 Kraków, Poland; E-mail: [a.wolnicka-glubisz@uj.edu.pl](mailto:a.wolnicka-glubisz@uj.edu.pl), Tel.: (+48)126646526






**FIGURE S1** Frequency of mutations in RIPK4 in human melanoma obtained from cBioPortal. The Cancer Genome Atlas (TCGA) was queried for mutations in the *RIPK4* gene. Shown are the frequencies of mutations for all datasets, out of 447, in which mutations in RIPK4 were identified




**FIGURE S2** Effect of siRNA down-regulation of RIPK4 on cells proliferation. **(a)**, Cell cycle profiles 72 h after transfection on WM266.4 and A375. **(b)** cell proliferation by cell counting



**FIGURE S3** Architecture of F-actin and vinculin 48 h after transfection WM266.4 cells with neg.si (scrambled control, upper left), RIPK4.si1 (upper right), and RIPK4.si2 (lower left)



**FIGURE S4** Architecture of F-actin and vinculin 48 h after transfection A375 cells with neg.si (scrambled control, upper left), RIPK4.si1 (upper right), and RIPK4.si2 (lower left)



**FIGURE S5.** Motile activity correlates with p-p65 levels in melanoma cells after PMA treatment. Cells were treated with PMA or DMSO for (a) 2 h or (b,c) 48 h. \*\*  $P < 0.001$